104 related articles for article (PubMed ID: 7719240)
1. Recombinant interferon alpha 2a, thymopentin and low doses of cytosine arabinoside for the treatment of myelodysplastic syndromes: a pilot study.
Venditti A; Scimò MT; del Poeta G; Buccisano F; Stasi R; Mastino A; Grelli S; Favalli C; Garaci E; Papa G
Leuk Lymphoma; 1995 Jan; 16(3-4):335-42. PubMed ID: 7719240
[TBL] [Abstract][Full Text] [Related]
2. A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes.
Venditti A; Tamburini A; Buccisano F; Scimò MT; Del Poeta G; Maurillo L; Cox MC; Abruzzese E; Tribalto M; Masi M; Amadori S
Ann Hematol; 2000 Mar; 79(3):138-42. PubMed ID: 10803936
[TBL] [Abstract][Full Text] [Related]
3. Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.
Fukuhara T; Miyake T; Maekawa I; Kurosawa M; Suzuki S; Noto S; Mori A; Chiba K; Toyoshima T; Hirano T; Morioka M; Tsutsumi Y; Okabe M; Kakinoki Y
Int J Hematol; 2000 Jun; 71(4):366-71. PubMed ID: 10905057
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-3 plus low-dose cytosine arabinoside for advanced myelodysplasia: a pilot study. EORTC Leukemia Group.
Gerhartz HH; Zwierzina HH; Walther J; Fenaux P; Hayat M; Jacobs A; Hoffbrand AV; Dardenne M; Solbu G; Suciu S
Cancer Invest; 1996; 14(4):299-306. PubMed ID: 8689423
[TBL] [Abstract][Full Text] [Related]
5. Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients.
Li JM; Shen Y; Wu DP; Liang H; Jin J; Chen FY; Song YP; Song EY; Qiu XF; Hou M; Qiu ZC; Shen ZX
Int J Hematol; 2005 Jul; 82(1):48-54. PubMed ID: 16105759
[TBL] [Abstract][Full Text] [Related]
6. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
Haematologica; 1997; 82(6):660-3. PubMed ID: 9499664
[TBL] [Abstract][Full Text] [Related]
7. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
Haematologica; 1997; 82(5 Suppl):9-12. PubMed ID: 9402747
[TBL] [Abstract][Full Text] [Related]
8. Treatment of advanced myelodysplastic syndromes with recombinant interferon-alpha 2b.
Aul C; Gattermann N; Schneider W
Eur J Haematol; 1991 Jan; 46(1):11-6. PubMed ID: 1988303
[TBL] [Abstract][Full Text] [Related]
9. All trans retinoic acid with low dose cytosine arabinoside in the treatment of myelodysplastic syndrome.
Nair R; Nair CN; Advani SH
Leuk Lymphoma; 1998 Mar; 29(1-2):187-92. PubMed ID: 9638988
[TBL] [Abstract][Full Text] [Related]
10. Phase I-II study of dose intensified chemotherapy with filgrastim and thymopentin in patients with advanced cancer.
Recchia F; De Filippis S; Ginaldi L; Quaglino D; Gulino A; Frati L; Rea S
Clin Ter; 1997; 148(5-6):201-7. PubMed ID: 9377855
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group.
Gerhartz HH; Marcus R; Delmer A; Zwierzina H; Suciu S; Dardenne M; Solbu G; de Witte T; Jacobs A; Visani G
Leukemia; 1994 Jan; 8(1):16-23. PubMed ID: 8289481
[TBL] [Abstract][Full Text] [Related]
12. A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma.
Grem JL; McAtee N; Murphy RF; Balis FM; Steinberg SM; Hamilton JM; Sorensen JM; Sartor O; Kramer BS; Goldstein LJ
J Clin Oncol; 1991 Oct; 9(10):1811-20. PubMed ID: 1919632
[TBL] [Abstract][Full Text] [Related]
13. Single weekly cytosine arabinoside and oral 6-thioguanine in patients with myelodysplastic syndrome and acute myeloid leukemia.
Munshi NC; Tricot GJ
Ann Hematol; 1997 Mar; 74(3):111-5. PubMed ID: 9111423
[TBL] [Abstract][Full Text] [Related]
14. Treatment with cytosine arabinoside and granulocyte colony-stimulating factor in patients with myelodysplastic syndrome and its leukemic phase.
Im T; Yamane T; Mugitani A; Hiyoshi M; Park K; Tatsumi N
Int J Hematol; 1994 Oct; 60(3):215-23. PubMed ID: 7532031
[TBL] [Abstract][Full Text] [Related]
15. Limited activity of mini-dose interferon alpha-2a in the treatment of myelodysplastic syndrome.
Maerevoet M; Van Den Neste E; Delannoy A; Ferrant A; Martiat P; Bosly A; Fauchet M; Michaux JL
Leuk Lymphoma; 1996 May; 21(5-6):519-20. PubMed ID: 9172821
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of myelodysplastic syndrome using continual subcutaneous infusion of low doses of cytosine arabinoside].
Vozobulová V; Koza V; Cepelák V; Neuwirtová R; Masek Z
Vnitr Lek; 1990 May; 36(5):483-8. PubMed ID: 2375080
[TBL] [Abstract][Full Text] [Related]
17. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
[TBL] [Abstract][Full Text] [Related]
19. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study.
Miller KB; Kim K; Morrison FS; Winter JN; Bennett JM; Neiman RS; Head DR; Cassileth PA; O'Connell MJ
Ann Hematol; 1992 Oct; 65(4):162-8. PubMed ID: 1420504
[TBL] [Abstract][Full Text] [Related]
20. GM-CSF and low-dose cytosine arabinoside in high-risk, elderly patients with AML or MDS.
Winer ES; Miller KB; Chan GW
Oncology (Williston Park); 2005 Apr; 19(4 Suppl 2):11-4. PubMed ID: 15934494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
